The diagnostics of colorectal cancer

Introduction

In 2009, in Poland colorectal cancer (CRC) was the third most commonly observed (after lung cancer and prostate cancer in men and breast cancer and lung cancer in women) neoplasm in both genders [1, 2]. Approximately, one in three people with colorectal cancer dies as a result of the disease, which is a significant proportion (7.1% of men and 7.9% of women) of all deaths connected with neoplasm [1]. CRC more frequently affects citizens of well-developed countries in comparison to poorly-developed countries. The higher number of patients with colorectal cancer in well-developed countries is connected with predisposition to carcinogenesis: low physical activity, high calorie and fat diet, obesity and a sedentary lifestyle [3]. In Poland, 11 thousand new cases of CRC are noted annually and approximately 8 thousand patients die [4, 5].

In Western Europe, a decrease in mortality rate connected with CRC is observed and the percentage of total recoveries is 65%, which is connected with early diagnostics and treatment of CRC [6]. In Poland, the percentage of total recoveries is approximately 30–35%. The reason for such huge differences is late recognition, frequently in the stage when metastases to the distant organs (mainly liver) are noticed [8, 9].

Despite genetic changes in CRC, epigenetic disorders are also observed which influence the response to treatment. It has been proved that in some groups of patients carcinogenesis is a result of DNA methylation and covalent modification of histones [4, 10].

Current oncological diagnostics emphasizes the necessity of early recognition of neoplasms, even in an asymptomatic or pre-cancerous stage [11]. Early recognition of CRC is extremely important in patients with acute symptoms and adverse course of the disease (approx. 155), due to the fact that CRC may cause severe intestinal perforation as a result of obstructive ileus [12]. It is estimated that > 50% of patients will develop colonic polyps; in 6% of them increased risk of CRC is noted [13]. Screening examinations, in order to recognize and remove adenomatous polyps, are extremely important in prevention of colorectal cancer [14].

Invasive examination

The simplest method of CRC recognition, along with the case history, is per rectum examination. During this examination, 70% of rectal cancers and 30% of CRCs are recognized. The accuracy of the examination increases with the experience of the doctor [15, 16].

Endoscopy

The most commonly applied and the most efficient method in diagnostics of CRC is endoscopy [6,7]. It includes sigmoidoscopy and colonoscopy. These examinations allow one to localize the tumor and take part of the large intestine for histological examination. Sensitivity and specificity of sigmoidoscopy for polyps and extended CRCs recognition is 92–97%. Sigmoidoscopy allows one to see only the lower part of the colon and rectum. Colonoscopy allows one to obtain an image of the whole intestine with similar sensitivity and specificity [15, 16]. In comparison to other screening examinations, colonoscopy has many more advantages: it is performed in less distant time points and increases the acceptance and tolerance of recent sedative techniques [17]. The research which included patients with average risk of CRC after colonoscopy showed a 67% decrease in the morbidity rate and a 65% decrease in the mortality rate in comparison to the control group. Endoscopy (sigmoidoscopy) may be applied in diagnostics of CRC as well as in palliative procedures in patients disqualified from surgical treatment (according to severity of the tumor or co-morbidities). Such procedures include methods enabling clearing of the obstruction connected with cancer [18]. Despite many advantages, endoscopy is an invasive method and often causes discomfort in patients [19]. What is more, colonoscopy brings the risk of perforation or bleeding from the large intestine. The risk of complications leads to patients avoiding and postponing the examination [20]. Recently, noninvasive virtual colonoscopy is more frequently applied. It allows one to obtain a 3D image of the large intestine with simultaneous application of computed tomography. Application of virtual colonoscopy decreases the risk of complications connected with perforation or bleeding from the large intestine [15, 19].

Imaging tests are also helpful in diagnostics of CRC, including roentgenographic examination of the thorax (Rtg), endorectal ultrasonography (USG), abdominal USG, computed tomography (CT) and nuclear magnetic resonance (NMR). However, these methods are efficient only in case of severe focal lesions [4]. What is more, positron emission computed tomography (PET/CT) is applied in colorectal cancer diagnostics. According to the fact that neoplasm may develop along with changes in metabolism of some chemical compounds, such as carbohydrates, in fluor-18-fluorodeoxyglucose positron emission computed tomography (18F-FDG PET/CT) 18F isotope-labeled deoxyglucose is used with the addition of the most common preparation, F18-FDG.

According to researchers, 18F-FDG-PET/CT shows the main prognostic value in response to treatment [46]. It was proved during FDG PET/CT at staging and after neoadjuvant chemoradiotherapy (mean 6.7 weeks) in 69 patients with locally developed rectal cancer that it is possible to stratify patients with rectal cancer before the surgery regardless of the method of image interpretation [42]. Capirci et al. [43] also presented the potential role of 18F-FDG-PET in secondary diagnostics after preoperative chemoradiotherapy in patients with locally developed rectal cancer and indicated that RI (response index) seems to be the best index of estimation of response to chemoradiotherapy.

Grasetto et al. [44] suggest that FDG-PET/CT along with routine evaluation of patients with colorectal cancer or with different neoplasms with metastases to the liver have a great impact on estimation of the stage of the disease and selection of suitable candidates for solitary liver metastasis resection and outcome.

In the diagnosis of colorectal cancer, 18F-FDG-PET/CT has an established role and an impact on the clinical image of patient.

In 18F-FDG-PET/CT, glucose metabolism does not depend on changes in the size of the tumor and tumor modification before and after the treatment is not connected with its morphological changes. 18F-FDG-PET/CT may be used for monitoring of the response to chemotherapy in patients with advanced colon cancer [46]. The researchers found that 18F-FDG-PET/CT has higher CT sensitivity in the detection of colorectal cancer metastases to the liver [46].

An increasing number of reports in the literature is observed proving that FDG PET is a powerful tool for monitoring the response results in GIST (gastrointestinal stromal tumors) and describing its central role in the evaluation of early response to treatment [45]. Researchers [45] reported a case where 18F-FDG PET/CT showed a very early treatment response in GIST, only 10 days after the beginning of the treatment, and was useful for 18 months follow-up. The examination may be clinically useful in many stages of colorectal cancer development [46].

At the moment, 18F-FDG-PET/CT is used the most frequently to evaluate the response to treatment after radio-chemotherapy in patients with advanced rectal cancer [46].

Noninvasive diagnostic methods

Fecal occult blood test



Fecal occult blood test is a simple, cheap and noninvasive diagnostic examination. The test reveals hemoglobin in feces, which indicates bleeding from the gastrointestinal tract. What is more, blood in feces is an unspecific indicator of CRC because it may derive not only from cancerous changes but also from polyps > 1–2 cm [14]. Repeating the test increases its sensitivity up to 90% [2].

The immunohistochemical fecal occult blood test (FIT) reveals human globin, a protein which builds hemoglobin along with heme and is also applied in CRC diagnostics [14].

Methods of molecular diagnostics are also applied including sDNA, which reveals changes in DNA in colorectal adenocarcinomas. DNA is stable in feces, which allows one to isolate and differentiate it from the DNA of bacteria [14]. Molecular diagnostics of CRC based on genetic and epigenetic tests has limited applicability. It is not commonly available and the expenses are relatively high [21]. Disadvantages of molecular diagnostics of CRC motivate the search for other biomarkers present in available biological material with lower costs.



Non-enzymatic tumor markers



Improvement of current CRC diagnostics is connected with non-enzymatic tumor markers [4]. Tumor markers are substances produced by tumor cells or healthy cells as a response to the tumor [22]. Markers may be applicable in screening tests, differential diagnostics, prognosis and in observation of disease progress. They may differentiate malignant from benign tumor in case of unspecific histological image [23]. Markers may be assayed in blood, urine and other body fluids [22].

Diagnostics and monitoring of CRC use: carcinoembryonic antigen (CEA), cancer antigen (CA) 19-9, tumor antigen of colorectal cancer (tumor-associated glycoprotein, TAG-72), tissue polypeptide specific antigen (TPS) and TAG-72 (Table 1). Increased values of tumor markers evaluate recurrences or metastases, especially to the liver [11]. Unfortunately, tumor markers recently applied in CRC diagnostics have insufficient sensitivity and organic specificity [24]. There is an urgent search for new, more sensitive and specific biomarkers of CRC.

CEA is the most frequently examined marker when gastrointestinal tract tumor is suspected [22]. The concentration over 5 µg/l is established as high [25]. CEA is a glycoprotein produced by cells of the large intestine. An increased level of CEA in serum may be connected with carcinogenesis. In 50% of patients it is an indicator of tumor recurrence after resection of the tumor. Unfortunately, increase of CEA concentration rarely occurs in early stages of the disease; usually it is observed in severe tumors [11, 22]. An increased level of CEA (> 5 µg/ml) before the operation may correlate with adverse prognosis [25]. According to Locker et al. [25], a sustained higher level of CEA in patients with metastases but without clinical symptoms allows one to qualify patients for more intense treatment, which in consequence extends the time of survival. Locker et al. [25] suggest estimation of CEA in treated patients with CRC every 1–3 months. Recent research showed that 15% of large intestine tumors do not reveal a higher level of CEA or release small amounts of CEA [11]. Increased concentration of CEA in serum may also occur in inflammatory conditions including hepatitis, inflammatory bowel disease (IBD), pancreatitis or obstructive pulmonary disease. CEA is highly specific in CRC but its sensitivity and validity are not sufficient for early cancer recognition [25, 26]. It has to be mentioned that results of CEA level estimation in the same portion of serum and in different laboratories may differ significantly [25].

CA 19-9 (carbohydrate antigen) is observed in gastrointestinal tract tumors. It is a glycoprotein with high molecular weight which may be released to the blood [27]. CA 19-9 is used in diagnostics of pancreatic, gastric and colorectal cancer [11]. According to the increase of CA 19-9 concentration in pancreatitis and liver disorders, the specificity of tests based on this antigen is limited [22]. CA 19-9 is applied in diagnostics and monitoring of CRC [14]. Similarly to CEA, it is not specific for a particular histological type of neoplasm and the organ which it derives from [27]. CA 19-9 is less sensitive than CEA [14]. Simultaneous estimation of CA 19-9 and CEA may increase diagnostic sensitivity in CRC recognition [27]. Simultaneous estimation of CA 19-9 and CEA is applied as a preoperative prognostic factor in evaluation of tumor stage and survival rate [11].

TPS (tissue polypeptide specific antigen) is a single conjugated polypeptide chain. It is formed in S and G2 phase of the molecular cycle and released to cells after mitosis [27]. TPS is applied in diagnostics and monitoring of chemotherapy in gastrointestinal tract tumors (mainly pancreatic and colorectal) and bronchial tumors [11]. Concentration of TPS in serum, closely connected with neoplasm cell proliferation, is a function of the cell division rate [27]. The upper limit of TPS in the physiological environment is 90 U/l. An increased level of TPS in neoplasms indicates hyperplasia of the tumor preceding the growth of its mass [28]. Estimation of TPS may be especially applicable in early stages of tumors. Increased concentration of TPS occurs in 60–80% of patients with CRC [26]. Michaeli et al. [29] observed an increased level of TPS in 75% of patients with histologically confirmed colon and rectal cancer. The time of survival was significantly shorter in patients with an initially high level of TPS. What is more, Michaeli et al. [29] suggest that TPS was more applicable than CEA in CRC monitoring. During estimation of TPS in patients with CRC increased levels of TPS may also be observed in autoimmune diseases and inflammatory lesions and the highest values occur in post-alcoholic hepatitis [27, 29].

TAG-72 (tumor-associated glycoprotein) is a glycoprotein produced by endothelium cells, renal pelvis cells, gastric epithelium and bile ducts. Diagnostic sensitivity, as a CRC marker, is 28–67%. It is recommended to estimate TAG-72 along with other markers, especially CEA [11].

Studies have been conducted on application in CRC diagnostics of other potential markers: protein mutation p-53, ras index, thymidine synthesis (TS), dihydropyrimidine dehydrogenase (DPD) and thymidine phosphatase (TP). These tissue markers have been used in prognosis of CRC treatment results, but they are useless in screening tests. It seems that the aforementioned potential markers may be applicable in CRC prognosis; however, there is no reason to apply them in CRC diagnostics [25].



Lysosomal exoglycosidases as potential CRC markers



Recently, studies have been conducted on application of lysosomal exoglycosidases as CRC markers including -mannosidase, -galactosidase and N-acetyl--D-hexosaminidase, its isoenzymes A and B and cathepsin D [30–32].

In the development of CRC, macrophages, mastocytes and neutrophils take part through the transformation of tumor cells. Development of CRC and its metastases may be supported by exoglycosidases released by macrophages [33, 34]. Szajda et al. [30, 31, 35] noted significant increase of HEX, HEX A, HEX B, GAL and FUC activity in serum and urine of patients with CRC. Waszkiewicz et al. [36] observed that the increase of lysosomal exoglycosidases and cathepsin D activity is connected with increased degradation and restoration of glycoconjugates in colorectal adenocarcinoma. A correlation has been observed between cathepsin D activity and HEX, HEX A, FUC and MAN activity in tumor tissue and urine along with a correlation between cathepsin D and GAL in urine [36]. Moreover, GAL in CRC participates in degradation of glycoconjugate oligosaccharide chains of colonic mucosa. Szajda et al. [30, 31] reported a significant increase of GAL activity in serum and urine of patients with CRC [31, 33]. Estimation of lysosomal exoglycosidases may be conducted in the majority of laboratories. The advantage of the test is its low cost as well as simplicity and repeatability. The disadvantage of lysosomal exoglycosidases is their unspecificity. Lysosomal exoglycosidase activity also increases in other neoplasms – pancreatic, thyroid, renal, ovarian and leukemias [37–39] – as well as such diseases as glomerulonephritis, hypertension, Sjögren syndrome, idiopathic arthritis and after liver transplantation [40].

In summary, it may be stated that analysis of single genes and tumor markers in prognostics of the disease is applicable, but frequently connected with insufficient sensitivity and specificity in routine clinical practice. Application of invasive examinations resolves almost all of the problems. However, it has to be mentioned that some patients do not want or cannot undergo the test due to its local unavailability. Gathering of feces samples for the blood occult test or DNA test may be conducted at home without bowel preparation. Patients should understand limitations and requirements of noninvasive tests – which are less efficient in prevention of the disease in comparison to invasive tests, should be conducted regularly and if the result is abnormal, invasive test will be necessary. What is more, for patients who are not able to repeat the test, noninvasive examinations should not be recommended due to their insufficiency [14]. The best solution seems to be estimation of at least two or three markers at the same time in order to increase their diagnostic applicability. It has to be mentioned that noninvasive tests should be conducted only during screening examination and therapy monitoring [41]. Estimation of lysosomal exoglycosidase activity should be considered as an additional CRC marker. Screening examination using tumor markers and intervention in early stages of CRC may significantly decrease the mortality rate connected with CRC. However, endoscopy is the most precise diagnostic method.



Scholarship Project “I’m studying, researching, commercialize – UMB doctoral support program” co-financed by the European Union under the European Social Fund.

References

 1. Wojciechowska U, Didkowska J, Zatoński W. Nowotwory złośliwe w Polsce w 2009 roku. Centrum Onkologii – Instytut im. M. Skłodowskiej-Curie, Warszawa 2011.

 2. Wronkowski Z, Brużewicz S. Nowotwory jelita grubego. Wydawnictwo Lekarskie PZWL, Warszawa 2008; 9-26, 44, 53-6.

 3. Gunter MJ, Leitzmann MF. Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. J Nutr Biochem 2006; 17: 145-56.

 4. Krakowczyk Ł, Strzelczyk JK. Epigenetyczna modyfikacja ekspresji genów w rozwoju raka jelita grubego. Wspolczesna Onkol 2007; 11: 289-94.

 5. Akouchekian M, Houshmand M. Mitochondrial haplogroup analysis in analysis in colorectal cancer: identification of a high-risk population. Arch Med Sci 2008; 12: 397-400.

 6. Olędzik J. Chirurgiczne leczenie nowotworów jelita grubego. Wspolczesna Onkol 2006; 10: 137-8.

 7. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR; United States Multi-Society Task Force on Colorectal Cancer. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2012; 143: 844-57.

 8. Gonciarz M, Pierzchalski P, Lorens K, Pawlik W, Petelez M. Genetyczne aspekty karcynogenezy w jelicie grubym. Wiad Lek 2004; 17: 74-9.

 9. Korniluk J, Wcisło G, Murzyński P, Stec R, Bodnar L, Obrocka B, Szczylik C. Epidemiologia raka jelita grubego. Wspolczesna Onkol 2006; 10: 136.

10. Rawson JB, Bapat B. Epigenetic biomarkers in colorectal cancer diagnostics. Expert Rev Mol Diagn 2012; 12: 499-509.

11. Ławicki S, Mroczko B, Szmitkowski M. Markery nowotworowe przydatne w diagnostyce i monitorowaniu raka jelita grubego. Post Hig Med Dośw 2002; 56: 617-34.

12. Ćwik G, Solecki M, Ciechański A, Prystupa A, Pedowski T, Wallner G. Perforacje w obrębie jelita grubego. Prz Gastroenterol 2012; 7: 125-32.

13. Ahlquist DA. Molecular detection of colorectal neoplasia. Gastroenterology 2010; 138: 2127-39.

14. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a jointguideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008; 134: 1570-95.

15. Cieśla P, Cieśla B, Cieślak H. Znaczenie profilaktyki wtórnej w nowotworze jelita grubego. Problemy Pielęgniarstwa 2008; 16: 316-20.

16. Gonciarz M, Małuch P, Borowicz M, Panuś K. Sporadyczny i wrodzony rak jelita grubego. Lekarz 2005; 7-8: 74-83.

17. Kahi CJ, Anderson JC, Rex DK. Screening and surveillance for colorectal cancer: state of the art. Gastrointest Endosc 2013; 77: 335-50.

18. Rydzewska G. Zaawansowane nowotwory jelita grubego – rola endoskopii. Świat Medycyny i Farmacji 2007; 10: 10.

19. Veerappan GR, Brooks DC. Czy kolonoskopia metodą tomografii komputerowej powinna zastąpić kolonoskopię optyczną w badaniach przesiewowych w kierunku raka jelita grubego? Med Prakt Onkol 2009; 4: 45-51.

20. Paduch R, Klatka J. Markery nowotworowe. Onkol Pol 2003; 6: 77-82.

21. Legolvan MP, Taliano RJ, Resnick MB. Application of molecular techniques in the diagnosis, prognosis and management of patients with colorectal cancer: a practical approach. Human Pathol 2012; 8: 1157-68.

22. Dziki A. Przedoperacyjna diagnostyka chorych z rakiem jelita grubego. Świat Med Farm 2007; 10: 11.

23. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996; 88: 1456-66.

24. Bartkowiak J, Jabłkowski M, Białkowska J, Dębieć-Rychter M. Markery nowotworowe w diagnostyce onkologicznej – teraźniejszość i przyszłość. Nowa Klinika 1998; 5: 948-54.

25. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC Jr; ASCO. ASCO 2006 Update of recommendations for the use of tumor markers in gastrointrestinal cancer. J Clin Oncol 2006; 33: 5319-27.

26. Theron EJ, Albrecht CF, Kruger PB, Jenkins K, van der Merwe MJ. Beta-glucosidase activity in fetal bovine serum renders the plant glucoside, hypoxoside, cytotoxic toward B16-F10-BL-6 mouse melanoma cells. In Vitro Cell Dev Biol Anim 1994; 30A: 115-9.

27. Partyka R, Sandelewski A, Łobejko I, Kocot J, Jałowiecki P, Kokocińska D. Przydatność oznaczeń rozpuszczalnego fragmentu cytokeratyny 18., antygenu karcynoembrionalnego oraz mucynopochodnego antygenu (CA 19-9) w diagnostyce chorych na raka okrężnicy i odbytnicy. Pol Merk Lek 2010; 29: 128-30.

28. Zawiska P, Dembowska M, Madaj K, Komenda J, Wilczek A. Ocena stężenia rozpuszczalnych fragmentów cytokeratyny 18 (TPS) i antygenu CA 125 w surowicy krwi chorych na marskość wątroby. Ann Soc Doctr Stud Acad Med Siles 2007; 33: 51-3.

29. Mishaeli M, Klein B, Sadikov E, Bayer I, Koren R, Gal R, Rakowsky E, Levin I, Kfir B, Schachter J, Klein T. Initial TPS serum level as an indicator of relapse and survival in colorectal cancer. Anticancer Res 1998; 18: 2101-6.

30. Szajda SD, Borzym-Kluczyk M, Snarska J, Puchalski Z, Zwierz K. N-acetylo--D-hexosaminidase and its isoenzymes A and B in blood serum and urine, as a potential colon cancer markers. Hepatogastroenterology 2009; 56: 1286-90.

31. Szajda SD, Snarska J, Borzym-Kluczyk M, Zalewska B, Waszkiewicz N, Bierć M, Zwierz K. Aktywność -galaktozydazy i -mannozydazy w surowicy krwi chorych z rakiem jelita grubego. Wspolczesna Onkol 2007; 11: 64-6.

32. Zwierz K, Midro AT. Zaburzenia metabolizmu u chorych z pierwotnym zespołem niedoborów cukrowych glikoprotein (CDG). Post Hig Dośw 1997; 51: 205-26.

33. Szajda SD, Jankowska A, Zwierz K. Carbohydrate markers in colon carcinoma. Dis Markers 2008; 25: 233-42.

34. Wilson PM, Labonte MJ, Lenz HJ. Molecular markers in the treatment of metastatic colorectal cancer. Cancer J 2010; 16: 262-72.

35. Szajda SD, Snarska J, Puchalski Z, Zwierz K. Lysosomalexoglycosidases in serum and urine of patients with colon adenocarcinoma. Hepatogastroenterology 2008; 55: 921-5.

36. Waszkiewicz N, Zalewska-Szajda B, Szajda SD, et al. Lysosomal exoglycosidases and cathepsin D in colon adenocarcinoma. Pol Arch Med Wewn 2012; 122: 551-6.

37. Choromańska B, Luto M, Szajda SD, et al. Aktywność N-acetylo--D-heksozoaminidazy i jej izoenzymów A i B w nowotworach. Post Hig Med Dosw 2011; 65: 752-8.

38. Chuaire-Noack L, Rondón-Lagos S, Sánchez-Corredor M, Ibán~ez-Pinilla M, Ramírez-Clavijo S. Beta-galactosidase activity as a marker of senescence in primary cultures of the ovarian surface epithelium. Invest Clin 2010; 51: 351-67.

39. Urbanelli L, Magini A, Ercolani L, Trivelli F, Polchi A, Tancini B, Emiliani C. Human lysosomal -D-mannosidase regulation in promyelocyticleukaemia cells. Biosci Rep 2011; 31: 477-87.

40. Olszewska E, Olszewski S, Borzym-Kluczyk M, Zwierz K. Role of N-acetyl--D-hexosaminidase in cholesteatoma tissue. Acta Bioch Pol 2007; 54: 365-70.

41. Tanaka T, Tanaka M, Tanaka T, Ishigamori R. Biomarkers for colorectal cancer. Int J Mol Sci 2010; 11: 3209-25.

42. Maffione AM, Ferretti A, Grassetto G, Bellan E, Capirci C, Chondrogiannis S, Gava M, Marzola MC, Rampin L, Bondesan C, Colletti PM, Rubello D. Fifteen different 18F-FDG PET/CT qualitative and quantitative parameters investigated as pathological response predictors of locally advanced rectal cancer treated by neoadjuvant chemoradiation therapy. Eur J Nucl Med Mol Imaging 2013; 40: 853-64.

43. Capirci C, Rubello D, Pasini F, Galeotti F, Bianchini E, Del Favero G, Panzavolta R, Crepaldi G, Rampin L, Facci E, Gava M, Banti E, Marano G. The role of dual-time combined 18-fluorodeoxyglucose positron emission tomography and computed tomography in the staging and restaging workup of locally advanced rectal cancer, treated with preoperative chemoradiation therapy and radical surgery. Int J Radiat Oncol Biol Phys 2009; 74: 1461-9.

44. Grassetto G, Fornasiero A, Bonciarelli G, Banti E, Rampin L, Marzola MC, Massaro A, Galeotti F, Del Favero G, Pasini F, Minicozzi AM, Al-Nahhas A, Cordiano C, Rubello D. Additional value of FDG-PET/CT in management of “solitary” liver metastases: preliminary results of a prospective multicenter study. Mol Imaging Biol 2010; 12: 139-44.

45. Musto A, Chondrogiannis S, Ferretti A, Crepaldi G, Marzola MC, Rampin L, Pasini F, Rubello D. 18F-FDG PET/CT may detect early response to Imatinib mesylate in GISTs with exon 11 mutation: case report and critical review of literature. OA Molecular Oncology 2013; 1: 1.

46. Grassetto G, Capirci C, Marzola MC, Rampin L, Chondrogiannis S, Musto A, Crepaldi G, Minicozzi AM, Massaro A, Rubello D. Colorectal cancer: prognostic role of 18F-FDG-PET/CT. Abdom Imaging 2012; 37: 575-9.



Address for correspondence



Prof. Krzysztof Zwierz MD, PhD

Medical College of the Universal Education Society

Mickiewicza 59

18-400 Łomża, Poland

tel. +48 85 741 24 81

e-mail: kszwie@gmail.com



Submitted: 7.06.2013

Accepted: 3.12.2013